Table 5.
Univariate analysis of prognostic factors affecting DFS and OS among 330 patients with at least two invasive tumor foci.
| Characteristics | p-value | |
|---|---|---|
| DFS | OS | |
| Age (<50 y/o vs. ≥50 y/o) | 0.741 | 0.277 |
| Menstrual status (Pre/Peri- vs. Post-) | 0.966 | 0.969 |
| Number of foci (2 vs. 3/4) | 0.264 | 0.557 |
| Location of foci (Multifocal vs. Multicentric) | 0.571 | 0.703 |
| Histology type (IDC vs. non-IDC) a | 0.802 | 0.789 |
| Tumor size (≤2.0 vs. >2.0 cm) a | 0.786 | 0.292 |
| ALN status (Negative vs. Positive) | 0.572 | 0.841 |
| Histological grade (I vs. II vs. III vs. NA)a | 0.637 | 0.892 |
| Molecular subtypea | 0.309 | 0.460 |
| Chemotherapy (No vs. Yes) | 0.698 | 1.000 |
| Endocrine therapy (No vs. Yes) | 0.102 | 0.458 |
| Anti-HER2 therapy (No vs. Yes) | 0.379 | 0.352 |
| Group (Homo vs. Hetero) | 0.041 | 0.059 |
a
Main focus.
ALN, axillary lymph node; IDC, invasive ductal carcinoma; DFS, disease-free survival; NA, not available; OS, overall survival; y/o, years old.